13,771 Shares in ANI Pharmaceuticals, Inc. $ANIP Bought by Virtus Advisers LLC

Key Points

• Virtus Advisers LLC has acquired a new stake in ANI Pharmaceuticals, purchasing 13,771 shares valued at approximately $922,000, making it the firm's 15th largest holding.
• Insider trading activity indicates significant shares sold, with Director Jeanne Thoma selling 21,540 shares for about $1.92 million, reflecting a 47.93% decrease in her holdings.
• ANI Pharmaceuticals reported a quarterly EPS of $1.80, exceeding expectations and reflecting a 53.2% revenue increase compared to the prior year.

Virtus Advisers LLC acquired a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 13,771 shares of the specialty pharmaceutical company's stock, valued at approximately $922,000. ANI Pharmaceuticals accounts for 1.2% of Virtus Advisers LLC's investment portfolio, making the stock its 15th largest position. Virtus Advisers LLC owned about 0.06% of ANI Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. National Bank of Canada FI acquired a new position in ANI Pharmaceuticals in the 1st quarter worth approximately $79,000. GAMMA Investing LLC boosted its stake in shares of ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after buying an additional 881 shares during the period. Mesirow Financial Investment Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at $206,000. Rafferty Asset Management LLC acquired a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at $200,000. Finally, Bridgefront Capital LLC acquired a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at $204,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ANIP. Guggenheim reissued a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Zacks Research raised shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 21st. Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research note on Monday, August 11th. Finally, HC Wainwright reissued a "buy" rating and set a $93.00 target price (up previously from $84.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $84.75.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 50,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $86.07, for a total transaction of $4,303,500.00. Following the transaction, the chief financial officer owned 180,863 shares in the company, valued at approximately $15,566,878.41. This trade represents a 21.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Chad Gassert sold 20,000 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $86.97, for a total transaction of $1,739,400.00. Following the transaction, the senior vice president owned 173,226 shares in the company, valued at $15,065,465.22. This represents a 10.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 405,538 shares of company stock worth $35,690,131 in the last ninety days. Company insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Stock Up 1.0%

Shares of ANI Pharmaceuticals stock traded up $0.97 during midday trading on Friday, reaching $93.50. 283,240 shares of the company's stock traded hands, compared to its average volume of 751,359. The company has a market cap of $2.03 billion, a price-to-earnings ratio of -121.43 and a beta of 0.61. The company's 50 day simple moving average is $73.39 and its 200 day simple moving average is $67.07. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $93.72.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. The business had revenue of $211.37 million for the quarter, compared to the consensus estimate of $187.18 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. ANI Pharmaceuticals's revenue for the quarter was up 53.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.02 EPS. Equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.